Hemolytic Anemia: Inherited Hemolytic Anemia, Enzyme Defects, Pyruvate Kinase Deficiency, Sickle Cell Anemia, Clinical Symptoms, Diagnosis and Treatment
Abstract
It is estimated that 42 percent of children under the age of five around the world suffer from anaemia, making it a global health problem. Anaemia is a condition that can be brought on by a variety of various causative factors, as is common knowledge. On the other hand, the pathogenetic mechanisms may be generally classified into three subtypes. These subtypes are a decrease in the synthesis of red blood cells (RBCs), an increase in the loss of RBCs, and an early destruction of RBCs. Two or more of these three mechanisms may overlap. The death of red cells and the release of components found inside the cell are both characteristics of the process known as hemolysis. When a person has hemolytic anaemia, their red blood cells (RBC), which ordinarily have a lifespan of between 100 and 120 days, have a shorter lifespan. Both extravascular and intravascular regions are capable of causing the death of red blood cells (RBC). When it comes to the reticuloendothelial system, macrophages are the cells responsible for extravascular hemolysis. Within the context of clinical practice, it is challenging to differentiate between these two sites of hemolysis. The most significant diagnostic tool is usually the examination of the kid with a whole family history, symptoms, and physical and laboratory results on admission. Although there are vast lists of markers that indicate certain types of hemolysis, the most essential diagnostic tool is always the paediatric evaluation. In addition, the key indicators can be described as the lack of haptoglobin, the presence of hemoglobinuria and hemosiderinuria, and the presence of hemosiderinuria. These are the major markers for intravascular hemolysis. Genetic illnesses known as inherited hemolytic anaemias (IHAs) are characterised by the presence of anaemia as a consequence of the increased destruction of aberrant red blood cells (RBCs) during circulation. Membranopathies, hemoglobinopathies, and enzymopathies are the three primary disorders that are used to categorise the abnormalities experienced by red blood cells (RBCs). Historically, the diagnosis of IHA has been carried out through a sequential method that combines clinical and laboratory results. These days, the aetiology of IHA is thought to be caused by germline mutations of the genes that are responsible for coding for the structural components of red blood cells (RBCs). Recent developments in molecular technologies, such as next-generation sequencing, have inspired us to use these technologies as a first-line method for the discovery of possible mutations and to determine the unique genes that are responsible for the development of IHAs in patients.
Full text article
References
Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med 1995;332:1317-1322.
Iolascon A, Miraglia del Giudice E, Perrotta S, et al. Hereditary spherocytosis: from clinical to molecular defects. Haematologica 1998;83:240-257. Olivieri NF, Brittenham GM. lron-chelating therapy and the treatment of thalassemia. Blood 1997;89:739-761.
Rosse WF. Paroxysmal nocturnal hemoglobinuria as a molecular disease. Medicine 1997;76:63-93. Steinberg MH. Management of sickle cell disease. N Engl J Med 1999;340:1027-1030. Weatherall DJ. The hereditary anemias. Br Med J 1997;314:492-496.
Jacobasch G, Rapoport SM. Hemolytic anemias due to erythrocyte enzyme deficiencies. Mol Aspects Med 1996;17: 143-70.
Zanella A, Fermo E, Bianchi P, Valentini G. Red cell pyruvate kinase deficiency: molecular and clinical aspects. Br J Haematol 2005;130:11-25.
Parker CJ. Paroxysmal nocturnal hemoglobinuria. Curr Opin Hematol 2012;19:141-8. 8. Gallagher PG. Diagnosis and management of rare congenital nonimmune hemolytic disease. Hematology Am Soc Hematol Educ Program 2015;2015:392-9.
Park ES, Jung HL, Kim HJ, et al. Hereditary hemolytic anemia in Korea from 2007 to 2011: A study by the Korean Hereditary Hemolytic Anemia Working Party of the Korean Society of Hematology. Blood Res 2013;48:211-6.
Barcellini W, Fattizzo B. Clinical applications of hemolytic markers in the differential diagnosis and management of hemolytic anemia. Dis Markers 2015;2015:635670. 11. King MJ, Zanella A. Hereditary red cell membrane disorders and laboratory diagnostic testing. Int J Lab Hematol 2013;35:237-43.
Christensen RD, Nussenzveig RH, Yaish HM, Henry E, Eggert LD, Agarwal AM. Causes of hemolysis in neonates with extreme hyperbilirubinemia. J Perinatol 2014;34:616-9.
van der Harst P, Zhang W, Mateo Leach I, et al. Seventy-five genetic loci influencing the human red blood cell. Nature 2012;492:369-75.
Bolton-Maggs PH, Langer JC, Iolascon A, Tittensor P, King MJ; General Haematology Task Force of the British Committee for Standards in Haematology. Guidelines for the diagnosis and management of hereditary spherocytosis-2011 update. Br J Haematol 2012;156:37-49.
Bianchi P, Fermo E, Vercellati C, et al. Diagnostic power of laboratory tests for hereditary spherocytosis: a comparison study in 150 patients grouped according to molecular and clinical characteristics. Haematologica 2012;97:516-23.
King MJ, Garçon L, Hoyer JD, et al. ICSH guidelines for the laboratory diagnosis of nonimmune hereditary red cell membrane disorders. Int J Lab Hematol 2015;37:304-25.
King MJ, Behrens J, Rogers C, Flynn C, Greenwood D, Chambers K. Rapid flow cytometric test for the diagnosis of membrane cytoskeleton-associated haemolytic anaemia. Br J Haematol 2000;111:924-33.
Farias MG. Advances in laboratory diagnosis of hereditary spherocytosis. Clin Chem Lab Med 2017;55:944-8.
Frickhofen N, Chen ZJ, Young NS, Cohen BJ, Heimpel H, Abkowitz JL. Parvovirus B19 as a cause of acquired chronic pure red cell aplasia. Br J Haematol 1994;87:818-24.
Hassoun H, Vassiliadis JN, Murray J, et al. Characterization of the underlying molecular defect in hereditary spherocytosis associated with spectrin deficiency. Blood 1997;90:398-406.
Mariani M, Barcellini W, Vercellati C, et al. Clinical and hematologic features of 300 patients affected by hereditary spherocytosis grouped according to the type of the membrane protein defect. Haematologica 2008;93:1310-7.
Delaunay J. The molecular basis of hereditary red cell membrane disorders. Blood Rev 2007;21:1-20.
Iolascon A, Miraglia del Giudice E, Perrotta S, Alloisio N, Morlé L, Delaunay J. Hereditary spherocytosis: from clinical to molecular defects. Haematologica 1998;83:240-57.
Eber SW, Gonzalez JM, Lux ML, et al. Ankyrin-1 mutations are a major cause of dominant and recessive hereditary spherocytosis. Nat Genet 1996;13:214-8.
Eber S, Lux SE. Hereditary spherocytosis--defects in proteins that connect the membrane skeleton to the lipid bilayer. Semin Hematol 2004;41:118-41.
Park J, Jeong DC, Yoo J, et al. Mutational characteristics of ANK1 and SPTB genes in hereditary spherocytosis. Clin Genet 2016;90:69-78.
Da Costa L, Galimand J, Fenneteau O, Mohandas N. Hereditary spherocytosis, elliptocytosis, and other red cell membrane disorders. Blood Rev 2013;27:167-78.
Glele-Kakai C, Garbarz M, Lecomte MC, et al. Epidemiological studies of spectrin mutations related to hereditary elliptocytosis and spectrin polymorphisms in Benin. Br J Haematol 1996;95: 57-66.
Dhermy D, Schrével J, Lecomte MC. Spectrin-based skeleton in red blood cells and malaria. Curr Opin Hematol 2007;14:198- 202.
Gallagher PG, Weed SA, Tse WT, et al. Recurrent fatal hydrops fetalis associated with a nucleotide substitution in the erythrocyte beta-spectrin gene. J Clin Invest 1995;95:1174-82.
Hirtz D, Kirkham FJ. Sickle cell disease and stroke. Pediatr Neurol 2019; 95: 34-41. 14. Kato GJ, Piel FB, Reid CD, et al. Sickle cell disease. Nat Rev Dis Primers 2018; 4: 18010.
Sant’Ana PG, Araujo AM, Pimenta CT, et al. Clinical and laboratory profile of patients with sickle cell anemia. Rev Bras Hematol Hemoter 2017; 39: 40-5.
Yawn BP, Buchanan GR, Afenyi-Annan AN, et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA 2014; 312: 1033-48.
Chou ST, Alsawas M, Fasano RM, et al. American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support. Blood Adv 2020; 4: 327-55.
Antmen B, Karakaş Z, Yeşilipek MA, et al. Deferasirox in children with transfusion-dependent thalassemia or sickle cell anemia: A large cohort real-life experience from Türkiye (REACH-THEM). Eur J Haematol 2019; 102: 123-30.
Kutlar A, Kanter J, Liles DK, et al. Effect of crizanlizumab on pain crises in subgroups of patients with sickle cell disease: A SUSTAIN study analysis. Am J Hematol 2019; 94: 55-61.
Herity LB, Vaughan DM, Rodriguez LR, Lowe DK. Voxelotor: a novel treatment for sickle cell disease. Ann Pharmacother 2021; 55: 240-5.
Niihara Y, Miller ST, Kanter J, et al. A phase 3 trial of l-glutamine in sickle cell disease. N Engl J Med 2018; 379(3): 226-35.
Demirci S, Uchida N, Tisdale JF. Gene therapy for sickle cell disease: An update. Cytotherapy 2018; 20: 899-910.
Cho HS, Hah JO, Kang IJ, et al. Hereditary hemolytic anemia in Korea: a retrospective study from 1997 to 2006. Korean J Hematol 2007;42:197-205.
Han E, Kim A, Park J, et al. Spectrin Tunis (Sp alpha (I/78)) in a Korean family with hereditary elliptocytosis. Ann Lab Med 2013;33:386-9.
Hoffman R, Benz EJ Jr, Silberstein LE, Heslop H, Weitz J, Anastasi J. Hematology: basic principles and practice. 6th ed. Philadelphia, PA: Elsevier Saunders, 2013:418-26.
Niss O, Chonat S, Dagaonkar N, et al. Genotype-phenotype correlations in hereditary elliptocytosis and hereditary pyropoikilocytosis. Blood Cells Mol Dis 2016;61:4-9.
Prchal JT, Gregg XT. Red cell enzymes. Hematology Am Soc Hematol Educ Program 2005:19-23.
Koralkova P, van Solinge WW, van Wijk R. Rare hereditary red blood cell enzymopathies associated with hemolytic anemia - pathophysiology, clinical aspects, and laboratory diagnosis. Int J Lab Hematol 2014;36:388-97.
Vives i Corrons JL. Chronic non-spherocytic haemolytic anaemia due to congenital pyrimidine 5' nucleotidase deficiency: 25 years later. Baillieres Best Pract Res Clin Haematol 2000;13:103-18.
Kahn A, Kaplan JC, Dreyfus JC. Advances in hereditary red cell enzyme anomalies. Hum Genet 1979;50:1-27.
Fiorelli G, Martinez di Montemuros F, Cappellini MD. Chronic non-spherocytic haemolytic disorders associated with glucose6-phosphate dehydrogenase variants. Baillieres Best Pract Res Clin Haematol 2000;13:39-55.
Zanella A, Fermo E, Bianchi P, Chiarelli LR, Valentini G. Pyruvate kinase deficiency: the genotype-phenotype association. Blood Rev 2007;21:217-31.
Canu G, De Bonis M, Minucci A, Capoluongo E. Red blood cell PK deficiency: An update of PK-LR gene mutation database. Blood Cells Mol Dis 2016;57:100-9.
Authors
Copyright (c) 2024 https://creativecommons.org/licenses/by/4.0/
This work is licensed under a Creative Commons Attribution 4.0 International License.